Advertisement

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Welcome and Introduction to Vi3C

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement

Aug

04

Today In Oncology

FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer

Quantum Machine Learning Framework Improves Prediction of Antigen Presentation and Immunotherapy Response

Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution

Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL

Advertisement

© 2026 HSP News Service, L.L.C.